advertisement
Odani-Kawabata N 15
Showing records 1 to 15 | Display all abstracts from Odani-Kawabata N95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Fuwa M
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Olander KW
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Shimazaki A
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Sato MA; Abrams MA
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Jerkins GW
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Kirihara T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Lu F
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Taniguchi T; Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Dinh P
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Iwamura R; Yoneda K
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Odani-Kawabata N; Chabi A
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Kato M; Morishima K
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Shams NK
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Shams NK
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229